Pharmacological Strategies for Managing Hyperaldosteronism in Children: Current Insights

Ibtisam Khalaf Ayad Alanazi [1], Noor Matar Alanazi [2], Amal Bshit S Alenezi [3], Fahad Rushid Fahad Altamimi [4], Asma Shulaywih Sanad Alanazi [5], Thuraia Freeh A Alanazi [6], Aftan Matar Alainzy [7], Raedah Fadhi Alanazi [8], Reem Shannan Khazin Alanazi [9], Reem Basheet Samir Alenezi [10]

1- Nursing Specialist, Directorate of Health Affairs in the Northern Border Region, Saudi Arabia
2- Nursing Specialist, Maternity and Children's Hospital, Arar, Saudi Arabia
3- Nursing technician, Maternity and Children's Hospital, Arar, Saudi Arabia
4- Nursing technician, Baqaa Primary Health care Center, Hail, Saudi Arabia
5- Nursing technician, North Medical Tower, Arar, Saudi Arabia
6- Nursing technician, Al Faisaliah Southern Healthcare Center, Arar, Saudi Arabia
7- Nursing technician, Maternity and Children's Hospital, Arar, Saudi Arabia
8- Nursing technician, North Medical Tower, Arar, Saudi Arabia
9- Nursing technician, North Medical Tower, Arar, Saudi Arabia
10- Nurse, Maternity and Children's Hospital, Arar, Saudi Arabia

Abstract:

Hyperaldosteronism in children, characterized by excessive production of the hormone aldosterone, can lead to significant clinical challenges, including hypertension and electrolyte imbalances. The management of this condition often involves pharmacological strategies aimed at reducing aldosterone levels and mitigating its effects on the body. Mineralocorticoid receptor antagonists, such as spironolactone and eplerenone, are commonly used to block the action of aldosterone, thereby promoting sodium excretion and potassium retention. These medications can effectively lower blood pressure and improve metabolic profiles in affected children. Additionally, the use of angiotensin-converting enzyme (ACE) inhibitors may provide further benefit by inhibiting the renin-angiotensin-aldosterone system (RAAS), which is often overactive in hyperaldosteronism. In more complex cases, particularly those associated with adrenal adenomas or bilateral adrenal hyperplasia, surgical intervention may be necessary, but pharmacological management remains a cornerstone of treatment. Ongoing research is focusing on the long-term effects of these therapies, including potential impacts on growth and development in pediatric populations. Furthermore, individualized treatment plans that consider the child's age, weight, and comorbid conditions are essential for optimizing outcomes. Regular monitoring of blood pressure, serum electrolytes, and renal function is crucial in managing hyperaldosteronism effectively in children, ensuring that any adverse effects of medications are promptly addressed.

Keywords: Hyperaldosteronism, children, pharmacological management, mineralocorticoid receptor antagonists, spironolactone, eplerenone, ACE inhibitors, renin-angiotensin-aldosterone system, adrenal adenomas, bilateral adrenal hyperplasia, individualized treatment, monitoring, hypertension, electrolyte imbalances.

Introduction:

Hyperaldosteronism, characterized by excessive production of the hormone aldosterone, poses significant health challenges, particularly in the pediatric population. Aldosterone plays a crucial role in regulating sodium and potassium levels, as well as maintaining blood pressure. In children, hyperaldosteronism can lead to severe complications, including hypertension, hypokalemia, and metabolic alkalosis, which can adversely affect growth and development. The condition can be classified into primary hyperaldosteronism, often caused by adrenal adenomas or hyperplasia, and secondary hyperaldosteronism, which may result from conditions such as renal artery stenosis or heart failure. Given the potential for long-term health issues stemming from uncontrolled hyperaldosteronism, effective pharmacological management is essential [1].

Recent advances in our understanding of the pathophysiology of hyperaldosteronism have opened new avenues for treatment strategies. Traditionally, the management of hyperaldosteronism in children has relied heavily on surgical interventions, particularly in cases of primary hyperaldosteronism. However, the risks associated with surgery, along with the growing recognition of the condition's prevalence in pediatric patients, have necessitated the exploration of pharmacological alternatives. The current landscape of pharmacological strategies includes mineralocorticoid receptor antagonists, such as spironolactone and eplerenone, which are designed to inhibit the effects of aldosterone at the receptor level, thereby mitigating its hypertensive and hypokalemic effects. Additionally, newer agents targeting the renin-angiotensin-aldosterone system (RAAS) have emerged as potential therapeutic options [2].

The importance of individualized treatment plans cannot be overstated, as the response to pharmacological agents can vary significantly among children, influenced by factors such as age, underlying health conditions, and the severity of hyperaldosteronism. Moreover, the long-term effects of pharmacotherapy in pediatric patients remain an area of active research, as the implications for growth, development, and overall health must be carefully considered. Recent studies have begun to shed light on the efficacy and safety of these pharmacological interventions, providing valuable insights into their role in managing hyperaldosteronism in children [3].

Pathophysiology of Hyperaldosteronism: Mechanisms and Implications:

Aldosterone plays a critical role in the regulation of blood pressure and electrolyte balance. It acts primarily on the distal convoluted tubules and collecting ducts of the nephron, promoting sodium reabsorption and potassium excretion. The reabsorption of sodium leads to an increase in extracellular fluid volume, contributing to the increase in blood pressure. In a healthy individual, the secretion of aldosterone is tightly regulated by several factors, including the renin-angiotensin-aldosterone system (RAAS), serum potassium levels, and adrenocorticotropic hormone (ACTH) [4].

Hyperaldosteronism can be classified into primary and secondary forms. Primary hyperaldosteronism arises from autonomous hypersecretion of aldosterone, often due to adrenal adenomas, bilateral adrenal hyperplasia, or, very rarely, adrenal carcinoma. Secondary hyperaldosteronism, on the other hand, is a compensatory response to other conditions such as renal artery stenosis, heart failure, or cirrhosis, which stimulate the RAAS to increase aldosterone production [5].

The most common cause of primary hyperaldosteronism is an aldosterone-producing adenoma (APA). These benign tumors arise from adrenal cortical cells, leading to an overproduction of aldosterone that is not subject to the usual regulatory feedback mechanisms. Studies show that about 30% of individuals with primary hyperaldosteronism may present with bilateral adrenal hyperplasia. While these conditions are benign, they can elicit significant physiological changes due to increased levels of aldosterone [6].

Secondary hyperaldosteronism is more common than primary hyperaldosteronism and typically indicates an underlying pathology. Conditions triggering secondary hyperaldosteronism frequently involve volume depletion, decreased perfusion to the kidneys, or activation of the RAAS due to other pathological processes. For instance, in renal artery stenosis, the reduced blood flow to affected kidney areas stimulates renin release, promoting aldosterone secretion despite the presence of normal or elevated plasma aldosterone levels [7].

The pathophysiological mechanisms of hyperaldosteronism are primarily centered around the actions of aldosterone on various tissues. These mechanisms can be categorized into cardiovascular, renal, metabolic, and neurological effects [7].

One of the critical implications of hyperaldosteronism is its role in cardiovascular pathology. The chronic elevation of aldosterone leads to sodium and water retention, resulting in increased plasma volume and hypertension.

Prolonged exposure to high levels of aldosterone also contributes to endothelial dysfunction, vascular remodeling, and hypertrophy of the cardiac muscle, increasing risks for heart conditions such as left ventricular hypertrophy and cardiac arrhythmias. The relationship between hyperaldosteronism and cardiovascular morbidity emphasizes the importance of diagnosing and managing this condition promptly [8].

In the kidneys, aldosterone's action at the mineralocorticoid receptors enhances sodium reabsorption while promoting potassium and hydrogen ion excretion. The enhanced renal tubular reabsorption of sodium leads to an expansion of the extracellular fluid volume. Conversely, the increased loss of potassium can result in hypokalemia, which manifests clinically with muscle weakness, arrhythmias, and metabolic alkalosis. The kidneys might also exhibit a compensatory response to this hypokalemia by reducing renin release, further perpetuating a cycle of aldosterone excess [8].

Metabolic effects associated with hyperaldosteronism include alterations in glucose metabolism and insulin sensitivity. The mechanism by which excess aldosterone influences glucose homeostasis remains a topic of research; however, studies have indicated that aldosterone may lead to insulin resistance, potentially exacerbating or contributing to the development of type 2 diabetes mellitus. Additionally, the link between hyperaldosteronism and obesity suggests that elevated aldosterone levels could be a critical contributory factor in metabolic syndrome [9].

The neurological implications of hyperaldosteronism are intertwined with the electrolyte disturbances it causes. Hypokalemia, often seen in patients with hyperaldosteronism, can lead to neuromuscular symptoms including muscle weakness, fatigue, and, in severe cases, paralysis. Furthermore, the electrolyte imbalance induced by hyperaldosteronism can also result in alterations in mood and cognitive function, which are increasingly recognized in the clinical management of patients [9].

Diagnosis of hyperaldosteronism is typically made through a combination of clinical suspicion, biochemical testing, and imaging studies. The plasma aldosterone-to-renin ratio (ARR) is often one of the first screening tests used; a high ratio suggests primary hyperaldosteronism. Confirmatory tests, such as saline infusion tests, can then be utilized to establish the diagnosis. Following diagnosis, imaging of the adrenal glands (via CT or MRI) helps identify adenomas or hyperplasia [10].

Treatments aimed at addressing hyperaldosteronism may include surgical intervention for adenomas, mineralocorticoid receptor antagonists like spironolactone, and lifestyle modifications to control hypertension and potassium levels. The management of secondary hyperaldosteronism is primarily focused on addressing the underlying cause [10].

Clinical Presentation and Diagnosis of Hyperaldosteronism in Children:

Hyperaldosteronism primarily arises from two main categories: primary hyperaldosteronism (Conn's syndrome) and secondary hyperaldosteronism. Primary hyperaldosteronism is typically due to an adrenal adenoma or hyperplasia, whereas secondary hyperaldosteronism results from stimuli external to the adrenal glands, such as renal artery stenosis or heart failure. In children, the distinction between these forms can be crucial for determining appropriate management and treatment protocols [11].

While hyperaldosteronism is relatively rare in pediatric populations, its potential implications for long-term health underscore the importance of early identification and management. Elevated aldosterone levels can lead to electrolyte imbalances, hypertension, and other cardiovascular complications that can have lasting effects on a child’s development [11].

The clinical presentation of hyperaldosteronism in children can often be subtle and may mimic other common pediatric ailments. Key symptoms and signs include:

1. **Hypertension**: One of the hallmark features of hyperaldosteronism is elevated blood pressure. In children, hypertension can manifest in various ways, including headaches, visual disturbances, or fatigue. Tracking blood pressure over time is essential, as it may present as resistant

hypertension—high blood pressure that does not respond well to standard treatments.

2. **Electrolyte Imbalances**: Hyperaldosteronism typically leads to hypokalemia (low potassium levels) due to increased renal potassium excretion. Symptoms of hypokalemia such as muscle weakness, fatigue, palpitations, and cramping may present. Hypernatremia (high sodium levels) often accompanies this condition, potentially resulting in increased thirst and urination.
3. **Growth and Developmental Effects**: Chronic hypertension and electrolyte disturbances can adversely affect growth and development. Children may experience delayed growth or failure to thrive, sometimes attributed to the underlying hormonal imbalances rather than external factors.
4. **Metabolic Alkalosis**: Increased aldosterone levels can lead to metabolic alkalosis, where blood pH becomes elevated due to the excretion of hydrogen ions. Symptoms may include dizziness, muscle twitching, and irritability.
5. **Vague Symptoms**: In many cases, patients may present with nonspecific symptoms such as fatigue and behavioral changes, making the diagnosis challenging [12].

Diagnosis of Hyperaldosteronism

The diagnosis of hyperaldosteronism in children necessitates a careful approach, as it involves both clinical assessment and laboratory testing. The following steps outline the diagnostic pathway:

1. **Clinical Suspicion**: A thorough clinical evaluation is essential, especially in children presenting with resistant hypertension or unexplained electrolyte imbalances. A detailed family history should also be taken, as genetic factors may contribute to adrenal disorders.
2. **Laboratory Tests**:
   - **Serum Electrolytes**: Initial blood work should include serum sodium, potassium, and bicarbonate levels. The presence of hypokalemia and metabolic alkalosis may indicate hyperaldosteronism.
   - **Aldosterone Levels**: A plasma aldosterone concentration (PAC) test can confirm hyperaldosteronism. This is often performed alongside plasma renin activity (PRA) to calculate the aldosterone-to-renin ratio (ARR). A high ARR suggests primary hyperaldosteronism.
3. **Further Evaluation**: If primary hyperaldosteronism is suspected, additional imaging studies may be performed to assess the adrenal glands. High-resolution imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) can identify adrenal tumors or hyperplasia.
4. **Confirmatory Testing**: In some cases, a saline suppression test or an oral sodium loading test may be employed to confirm hyperaldosteronism. These tests evaluate the body’s aldosterone response to an increase in sodium intake or fluid volume.
5. **Functional Testing**: The assessment of 24-hour urine collections for sodium, potassium, and aldosterone can provide additional confirmation of the diagnosis, offering insight into the overall adrenal function.
6. **Genetic Testing**: In cases where familial syndromes are suspected, genetic testing may be indicated, especially in children with early-onset hyperaldosteronism or associated disorders [13].

Pharmacological Management: Overview of Current Treatment Options:

Hyperaldosteronism, also known as primary aldosteronism or Conn's syndrome, is a condition characterized by the excessive production of aldosterone, a hormone produced by the adrenal glands that plays a crucial role in regulating blood pressure and electrolyte balance. The overproduction of aldosterone leads to sodium retention, increased blood volume, hypertension, and potassium loss, which can result in hypokalemia. The management of hyperaldosteronism is essential to mitigate its cardiovascular risks and improve patient outcomes [14].

1. Mineralocorticoid Receptor Antagonists (MRAs)

The cornerstone of pharmacological treatment for primary hyperaldosteronism is the use of mineralocorticoid receptor antagonists, primarily spironolactone and eplerenone. These agents block the effects of aldosterone at the renal tubule level, leading to increased sodium excretion and potassium retention [15].

Spironolactone has been the traditional first-line treatment for hyperaldosteronism. It is a competitive antagonist of the mineralocorticoid receptor and also possesses anti-androgenic properties, which can be beneficial in certain patient populations, particularly women with conditions like hirsutism. Clinical studies have demonstrated that spironolactone effectively lowers blood pressure and corrects hypokalemia in patients with hyperaldosteronism. The typical starting dose ranges from 25 to 100 mg daily, with adjustments made based on the patient's response and serum potassium levels. However, spironolactone can cause side effects such as gynecomastia, menstrual irregularities, and gastrointestinal disturbances [16].

Eplerenone is a newer MRA that is more selective for the mineralocorticoid receptor and has a lower incidence of side effects related to androgen receptor antagonism. This selectivity makes eplerenone a suitable alternative for patients who experience significant side effects from spironolactone. Eplerenone has been shown to effectively manage hypertension and hyperaldosteronism, with a typical starting dose of 50 mg daily, which can be increased based on clinical response and tolerability. Studies suggest that eplerenone may offer similar efficacy to spironolactone while minimizing adverse effects [17].

2. Other Antihypertensive Agents

While MRAs are the primary treatment for hyperaldosteronism, additional antihypertensive agents may be necessary to achieve optimal blood pressure control, especially in patients with resistant hypertension. These agents include:

ACE inhibitors, such as lisinopril and ramipril, can be beneficial in managing hypertension in patients with hyperaldosteronism. These medications inhibit the renin-angiotensin-aldosterone system (RAAS), leading to decreased aldosterone production and improved blood pressure control. However, caution is warranted, as ACE inhibitors can lead to hyperkalemia, particularly in patients already at risk due to aldosterone antagonism [18].

ARBs, including losartan and valsartan, are another class of medications that can be used to manage hypertension in hyperaldosteronism. Like ACE inhibitors, ARBs block the effects of angiotensin II, thereby reducing aldosterone secretion and blood pressure. They may be preferred in patients who experience cough or angioedema with ACE inhibitors [19].

Calcium channel blockers, such as amlodipine and diltiazem, are effective antihypertensive agents that can be used alongside MRAs. They work by relaxing vascular smooth muscle and reducing peripheral resistance, contributing to lower blood pressure. These agents are generally well-tolerated and can be particularly useful in patients with concomitant coronary artery disease [20].

3. Emerging Therapies

Research into the pharmacological management of hyperaldosteronism is ongoing, with new therapies being explored. One promising area of investigation involves the use of selective aldosterone synthase inhibitors. These agents aim to inhibit the enzyme responsible for aldosterone production, potentially providing a more targeted approach to managing hyperaldosteronism without the side effects associated with MRAs [21].

Additionally, there is growing interest in the role of dual RAAS blockade, combining MRAs with ACE inhibitors or ARBs to achieve better blood pressure control and mitigate the effects of aldosterone. However, this approach requires careful monitoring for hyperkalemia and renal function [22].

Mineralocorticoid Receptor Antagonists: Efficacy and Safety Profiles:

Mineralocorticoid receptor antagonists (MRAs) are a class of pharmacological agents that play a critical role in treating various cardiovascular and renal disorders. By interfering with the action of mineralocorticoids, primarily aldosterone, these agents have garnered attention for their efficacy in managing hypertension, heart failure, and conditions characterized by excess mineralocorticoid activity, such as primary hyperaldosteronism [23].

Mineralocorticoids, such as aldosterone, are steroid hormones that primarily influence electrolyte balance and blood pressure regulation through the kidneys. They do so by enhancing sodium reabsorption and promoting potassium excretion, which can lead to fluid retention and increased blood pressure. MRAs act by competitively inhibiting the mineralocorticoid receptor, thus blocking the effects of aldosterone. This results in decreased sodium reabsorption, enhanced potassium retention, and ultimately, a reduction in blood volume and blood pressure [24].

1. **Hypertension**: MRAs have been established as effective antihypertensive agents. Clinical trials have demonstrated that spironolactone and eplerenone, when used as monotherapy or in combination with other antihypertensive medications, lead to significant reductions in blood pressure. Particularly in resistant hypertension, where patients struggle to achieve target blood pressure despite multiple drug therapies, MRAs have shown substantial benefit [25].

2. **Heart Failure**: The role of MRAs in heart failure, particularly in those with reduced ejection fraction (HFrEF), has been pivotal. The RALES (Randomized Aldactone Evaluation Study) trial and the EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial highlighted that the addition of MRAs to standard heart failure therapy not only reduces morbidity and mortality but also improves quality of life. By mitigating the effects of aldosterone, MRAs help prevent cardiac remodeling and dysfunction, thereby offering a clear survival benefit [26].

3. **Primary Hyperaldosteronism**: This condition is characterized by excessive secretion of aldosterone, often leading to hypertension and hypokalemia. MRAs are considered first-line treatment for this disorder. Spironolactone, specifically, has demonstrated effectiveness in normalizing blood pressure and potassium levels in patients with primary hyperaldosteronism, often providing a feasible alternative to surgical intervention [26].

4. **Chronic Kidney Disease (CKD)**: In patients with CKD, particularly those with diabetic nephropathy, MRAs can contribute to renal protection. They help in managing proteinuria independently of blood pressure control, which is crucial in slowing the progression of kidney disease [26].

Safety Profile

While MRAs present substantial therapeutic benefits, their use is not without risks. The most significant concern is the potential for hyperkalemia, especially in patients with impaired renal function or those taking concomitant medications that also raise potassium levels. Hyperkalemia can lead to serious cardiovascular complications; thus, regular monitoring of serum potassium levels is essential when initiating and maintaining therapy with MRAs [27].

Another safety issue is the risk of secondary endocrine effects associated with spironolactone. As it is a non-selective MRA, spironolactone can bind to other steroid hormone receptors, potentially provoking side effects such as gynecomastia, menstrual irregularities, and sexual dysfunction. Eplerenone, on the other hand, is designed to be more selective for the mineralocorticoid receptor, which may reduce these side effects, making it a preferable option for some patients [28].

The choice to initiate MRA therapy must be individualized, taking into account the patient's specific clinical context, renal function, and potential drug interactions. It is particularly crucial in older adults, who often experience polypharmacy and may have varying degrees of renal impairment. For patients with diabetes or those at risk for cardiovascular events, MRAs can provide a dual benefit by addressing hypertension and providing renal protective effects [29].

In the setting of heart failure, the introduction of MRAs must be approached cautiously when renal function is compromised. Clinical guidelines recommend careful titration of doses and periodic monitoring of renal function and electrolytes to ensure safety [29].

Role of ACE Inhibitors and Other Adjunctive Therapies:

The management of various cardiovascular conditions, particularly hypertension and heart failure, has evolved significantly over the years, guided by advances in pharmacology and a deeper understanding of pathophysiological mechanisms. Among the most prominent classes of medications utilized in this arena are angiotensin-converting enzyme (ACE) inhibitors. These drugs play a pivotal role in the management of cardiovascular diseases, often in tandem with other adjunctive therapies that enhance therapeutic outcomes, optimize patient health, and mitigate the risk of complications [30].

ACE inhibitors are a class of medications that inhibit the activity of the angiotensin-converting enzyme, a crucial component of the renin-angiotensin-aldosterone system (RAAS). This system plays a significant role in regulating blood pressure, fluid balance, and systemic vascular resistance. In conditions like hypertension and heart failure, the RAAS tends to become overactive, leading to increased levels of angiotensin II, a potent vasoconstrictor. This results in elevated blood pressure and increased workload on the heart [31].

By inhibiting the conversion of angiotensin I to angiotensin II, ACE inhibitors effectively lower blood pressure, reduce myocardial oxygen demand, and promote vasodilation. Common examples of ACE inhibitors include enalapril, lisinopril, ramipril, and captopril. These medications are well-researched and have demonstrated significant effects in reducing mortality and morbidity in patients with heart failure and in those who have suffered myocardial infarctions [32].

The benefits of ACE inhibitors extend beyond simple blood pressure reduction. In patients with heart failure, they contribute to improved ventricular remodeling, which is the process by which the heart's structure changes in response to injury or chronic pressure overload. By decreasing the workload of the heart and reducing the strain on ventricular walls, ACE inhibitors can significantly improve left ventricular function [33].

In post-myocardial infarction patients, ACE inhibitors are instrumental in reducing the risk of subsequent cardiovascular events. They not only lower the risk of heart failure but also contribute to overall improved cardiovascular outcomes by preventing pathological remodeling and fibrosis. The benefits extend to patients with diabetes and chronic kidney disease, as ACE inhibitors have shown renoprotective effects, delaying the progression of nephropathy [34].

Adjunctive Therapies

While ACE inhibitors are highly effective as monotherapy, they are often used in combination with other adjunctive therapies to enhance treatment outcomes. Some of these adjunctive therapies include:

1. **Angiotensin II Receptor Blockers (ARBs)**: In patients who cannot tolerate ACE inhibitors due to side effects such as cough or angioedema, ARBs serve as an alternative. They block the action of angiotensin II at the receptor level, providing similar benefits without some of the adverse effects associated with ACE inhibitors. Combination therapy with both ACE inhibitors and ARBs, although traditionally avoided, has been investigated in certain populations with heart failure to maximize the blockade of the RAAS [35].

2. **Beta-Blockers**: These medications slow the heart rate and decrease myocardial contractility, making them beneficial in heart failure management. When used in conjunction with ACE inhibitors, beta-blockers can help counter the neurohormonal activation that occurs in heart failure, further enhancing survival and functional capacity.

3. **Diuretics**: Often integrated into the treatment protocol for heart failure, diuretics help manage fluid overload by promoting renal excretion of sodium and water. While ACE inhibitors handle the underlying pathophysiological aspects, diuretics provide symptomatic relief from congestion, facilitating improved quality of life for patients.

4. **Aldosterone Antagonists**: Medications such as spironolactone and eplerenone block the effects of aldosterone, a hormone that can exacerbate heart failure by promoting sodium retention, potassium excretion, and cardiac remodeling. The addition of aldosterone antagonists to a regimen containing ACE inhibitors and beta-blockers has shown to further reduce mortality and hospitalizations in patients with severe heart failure.

5. **Lifestyle Modifications**: Beyond pharmacological interventions, lifestyle changes play a crucial role in managing hypertension and heart failure. Patients are encouraged to adopt heart-healthy dietary practices, engage in regular physical activity, limit sodium intake, and manage weight. Such lifestyle alterations can potentiate the effects of medications and generally improve cardiovascular health [35].

Monitoring and Management Considerations

The incorporation of ACE inhibitors and adjunctive therapies necessitates careful monitoring due to potential side effects and drug interactions. Key parameters to monitor include renal function, electrolytes (especially potassium levels due to the risk of hyperkalemia), blood pressure, and heart rate. In certain populations, such as those with renal impairment or volume status changes, individualized dosing and therapy adjustments may be required [36].

Additionally, patient education is paramount in the effective management of cardiovascular conditions. Patients should be informed about the importance of adherence to prescribed medications, the significance of regular follow-up appointments, and recognition of potential side effects needing immediate attention [37].

Challenges in Treatment: Adverse Effects and Monitoring Strategies:

The treatment of hyperaldosteronism can vary based on the underlying cause, patient health status, and the particularities of the condition. The primary treatment options include surgical intervention for unilateral aldosterone-producing adenomas and medical management for bilateral adrenal hyperplasia (BAH) or when surgery is not feasible. Each of these approaches comes with its own set of adverse effects that must be carefully considered [38].

1. **Surgical Interventions**: Surgical treatment usually involves the laparoscopic removal of an adrenal adenoma. While surgery can yield a cure for unilateral hyperaldosteronism, it is not without risks. Potential complications include hemorrhage, infection, and complications related to anesthesia. Additionally, patients undergoing adrenalectomy may experience sudden fluctuations in hormone levels, leading to postoperative adrenal insufficiency. Research suggests that careful patient selection and preoperative assessment can mitigate some of these risks, yet they remain concerning [39].

2. **Medical Management**: In cases where surgery is not an option, or for patients with BAH, mineralocorticoid receptor antagonists such as spironolactone and eplerenone are commonly prescribed. These medications can reduce blood pressure and restore electrolyte balance; however, they are also associated with notable adverse effects. Spironolactone, for instance, may lead to hyperkalemia, especially in patients with renal impairment, as it acts by inhibiting the renal excretion of potassium. Other potential side effects include gynecomastia, menstrual irregularities, and gastrointestinal disturbances. Eplerenone, while possessing a more favorable side effect profile in terms of hormonal effects,

still carries the risk of hyperkalemia and renal dysfunction [40].

3. **Additional Pharmacotherapy**: Other antihypertensive agents may be prescribed concurrently, such as ACE inhibitors or angiotensin II receptor blockers (ARBs). While these agents help manage hypertension, they can also exacerbate hyperkalemia when combined with aldosterone antagonists. Consequently, there is a delicate balance that clinicians must navigate when treating hypertensive patients with hyperaldosteronism, especially in the context of effective blood pressure control and maintaining electrolyte homeostasis [41].

Monitoring Strategies

Effective monitoring strategies are essential to identifying and mitigating the adverse effects of treatment for hyperaldosteronism. Given the complexity of the condition and the medications involved, a multifaceted approach is necessary to ensure patient safety and treatment efficacy [42].

1. **Blood Pressure Monitoring**: Patients must have their blood pressure regularly monitored, particularly during the initiation of treatment and after any changes in medication dosing or regimen. Regular follow-up visits allow clinicians to assess response to therapy and make necessary adjustments [43].

2. **Electrolyte Monitoring**: Routine electrolyte panels, especially for serum potassium levels, are critical in patients receiving mineralocorticoid receptor antagonists. Hyperkalemia can lead to severe clinical consequences, including potential cardiac arrhythmias. Monitoring should include baseline assessments before starting medication and periodic evaluations thereafter, especially during dose adjustments or in the presence of renal impairment [44].

3. **Renal Function Assessment**: Kidney function assessments through serum creatinine and estimated glomerular filtration rate (eGFR) evaluations are essential given the renal implications of both hyperaldosteronism and its treatment. Patients should undergo baseline renal function testing before the initiation of treatment and continue to be monitored regularly. In cases of deteriorating renal function, clinicians may need to reassess the treatment approach to avoid further complications [45].

4. **Long-term Follow-Up**: Patients with hyperaldosteronism require a structured long-term follow-up regimen to monitor for complications, including cardiovascular health and the potential for recurrent hypertension. Regular assessments of overall health, lifestyle factors, and adherence to treatment can significantly impact long-term outcomes [46].

5. **Patient Education and Involvement**: Educating patients about the symptoms of adverse effects, such as signs of hyperkalemia (e.g., muscle weakness, fatigue, palpitations), is crucial. Encouraging patients to be actively involved in their care facilitates better management outcomes, as they may be more likely to report unusual symptoms promptly [47].

Future Directions and Research Opportunities in Pediatric Hyperaldosteronism Management:

Pediatric hyperaldosteronism, a condition characterized by excessive production of the hormone aldosterone from the adrenal glands, can lead to significant health issues in children, such as hypertension, electrolyte imbalances, and cardiovascular complications. Historically more common in adults, recent findings indicate that the pediatric population may also be affected. Given the long-term implications of this condition, understanding its management and developing future directions for research is critical [48].

Hyperaldosteronism can be classified into primary and secondary forms. Primary hyperaldosteronism, often caused by adrenal adenomas or bilateral adrenal hyperplasia, results in autonomous hormone secretion, while secondary hyperaldosteronism arises from conditions such as renal artery stenosis or heart failure, which stimulate increased renin production. In the pediatric population, primary hyperaldosteronism is particularly noteworthy due to its distinct presentation and the challenges it poses in diagnosis and management [49].

The prevalence of hyperaldosteronism in children is still being assessed. Current estimates suggest that it may be underdiagnosed due to non-specific symptoms. Clinical manifestations include persistent hypertension, hypokalemia, and metabolic alkalosis, which can lead to further health complications if left untreated. Furthermore, early identification and management of pediatric hyperaldosteronism are essential to prevent long-term sequelae, including cardiovascular diseases and renal impairment [50].

Management of pediatric hyperaldosteronism has traditionally been approached using a combination of pharmacological treatment and surgical intervention, depending on the underlying cause. The mainstay drugs include mineralocorticoid receptor antagonists such as spironolactone, which effectively counteract the hypertensive effects of aldosterone and help to normalize electrolyte levels. In cases of adrenal adenomas, surgical resection has emerged as an effective strategy, demonstrating promising outcomes in both alleviating hypertension and restoring electrolyte balance [51].

Despite these available management options, there are several limitations. The efficacy and safety of long-term use of medications, particularly in a pediatric cohort, warrant cautious consideration. Additionally, the preoperative evaluation and surgical risk in children differ significantly from adults, highlighting a need for tailored approaches. Current protocols could benefit from further research in pediatric-friendly imaging techniques and criteria for optimal surgical candidates [52].

The future of pediatric hyperaldosteronism management is ripe with opportunities for innovative research. One promising avenue is the application of genomic medicine. As our understanding of the genetic underpinnings of hyperaldosteronism evolves, personalized medicine could lead to more effective treatments tailored to an individual child's genetic makeup. Identifying genetic markers associated with hyperaldosteronism could also improve early diagnosis in high-risk populations [53].

Moreover, the development of newer generations of medications that target the aldosterone pathway with fewer side effects is crucial. There is ongoing research into more selective mineralocorticoid receptor antagonists and drugs that potentially target the aldosterone biosynthesis pathway itself, offering alternatives to traditional treatments [54].

A multi-disciplinary approach to understanding and managing pediatric hyperaldosteronism can enhance the patient experience and treatment outcomes. Future research could focus on patient-centered care models, such as investigating the psychosocial impact of chronic conditions on children and their families, creating educational resources, and involving families in clinical decision-making. This could lead to improved adherence to treatment and better overall health outcomes [55].

Additionally, long-term cohort studies examining the outcomes of various management strategies in pediatric populations are essential. These studies can help establish best practices and treatment guidelines, inform future clinical trials, and ensure that the transitions from pediatric to adult care are smooth and effective [56].

The integration of technology into healthcare is another frontier in pediatric hyperaldosteronism management. Telemedicine offers promising avenues for monitoring and managing these patients. Regular follow-ups through digital platforms could enhance access to specialist care, provide education regarding medication adherence, and facilitate the timely monitoring of health parameters to prevent complications [57].

Furthermore, wearable technology may play a role in real-time monitoring of blood pressure and heart rates, creating a comprehensive dataset that can be analyzed for research and applied in clinical practice. This would allow for proactive management of hypertension and associated risks [58].

Conclusion:

In conclusion, the management of hyperaldosteronism in children presents unique challenges that require a comprehensive understanding of the condition's pathophysiology, clinical presentation, and treatment options. Pharmacological strategies, particularly the use of mineralocorticoid receptor antagonists such as spironolactone and eplerenone, have proven effective in mitigating the adverse effects of excess aldosterone, including hypertension and electrolyte imbalances. The integration of ACE inhibitors further enhances therapeutic outcomes by addressing the underlying dysregulation of the renin-angiotensin-aldosterone system.

However, careful consideration of each child's individual circumstances is essential, as factors such as age, weight, and coexisting health conditions can influence treatment efficacy and safety. Ongoing monitoring of blood pressure, serum electrolytes, and renal function is crucial to ensure optimal management and to minimize potential side effects. Future research is needed to explore long-term outcomes and the impact of various treatment modalities on growth and development in pediatric patients. By advancing our understanding of hyperaldosteronism and refining pharmacological approaches, we can improve the quality of care and health outcomes for affected children.

References:

1. Kim V, Shi J, An J, Bhandari S, Brettler JW, Kanter MH, Sim JJ. Hyperaldosteronism Screening and Findings From a Large Diverse Population With Resistant Hypertension Within an Integrated Health System. Perm J. 2024 Mar 15;28(1):3-13.
2. Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am. 2011 Jun;40(2):333-41, viii.
3. Fountain JH, Kaur J, Lappin SL. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 12, 2023. Physiology, Renin Angiotensin System.
4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V., GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021.
5. Dutta RK, Söderkvist P, Gimm O. Genetics of primary hyperaldosteronism. Endocr Relat Cancer. 2016 Oct;23(10):R437-54.
6. Memon SS, Bandgar T. Update on Primary Aldosteronism: Time to Screen All Hypertensives. J Assoc Physicians India. 2024 Jan;72(1):11-12.
7. Ananda RA, Gwini SM, Long KM, Lai JH, Chen G, Russell GM, Stowasser M, Fuller PJ, Yang J. Diagnostic Delay and Disease Burden in Primary Aldosteronism: An International Patient Survey. Hypertension. 2024 Feb;81(2):348-360.
8. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003 May;17(5):349-52.
9. Funder JW. The genetic basis of primary aldosteronism. Curr Hypertens Rep. 2012 Apr;14(2):120-4.
10. Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011 Feb 11;331(6018):768-72.
11. Huang WC, Lin YH, Wu VC, Chen CH, Siddique S, Chia YC, Tay JC, Sogunuru G,

Cheng HM, Kario K. Who should be screened for primary aldosteronism? A comprehensive review of current evidence. J Clin Hypertens (Greenwich). 2022 Sep;24(9):1194-1203.
12. Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013 Oct 04;6:129-38.
13. Lee FT, Elaraj D. Evaluation and Management of Primary Hyperaldosteronism. Surg Clin North Am. 2019 Aug;99(4):731-745.
14. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec;40(6):892-6.
15. Turcu AF, Nhan W, Grigoryan S, Zhang L, Urban C, Liu H, Holevinski L, Zhao L. Primary Aldosteronism Screening Rates Differ with Sex, Race, and Comorbidities. J Am Heart Assoc. 2022 Jul 19;11(14):e025952.
16. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115.
17. Ruhle BC, White MG, Alsafran S, Kaplan EL, Angelos P, Grogan RH. Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery. 2019 Jan;165(1):221-227.
18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul;34(28):2159-219.
19. Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, Chertow GM, Leppert JT, Bhalla V. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertension. 2020 Mar;75(3):650-659.
20. Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans: A Retrospective Cohort Study. Ann Intern Med. 2021 Mar;174(3):289-297.
21. Araujo-Castro M, Ruiz-Sánchez JG, Parra Ramírez P, Martín Rojas-Marcos P, Aguilera-Saborido A, Gómez Cerezo JF, López Lazareno N, Torregrosa Quesada ME, Gorrin Ramos J, Oriola J, Poch E, Oliveras A, Méndez Monter JV, Gómez Muriel I, Bella-Cueto MR, Mercader Cidoncha E, Runkle I, Hanzu FA., In representation of the following medical Spanish societies: Spanish Society of Endocrinology and Nutrition (SEEN), Spanish Society of Cardiology (SEC), Spanish Society of Nephrology (SEN), Spanish Society of Internal Medicine (SEMI), Spanish Radiology Society (SERAM), Spanish Society of Vascular and Interventional Radiology (SERVEI), Spanish Society of Laboratory Medicine (SEQC(ML), Spanish Society of Anatomic-Pathology, Spanish Association of Surgeons (AEC). Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism. Endocrine. 2024 Jul;85(1):99-121.

22. Conroy PC, Hernandez S, Graves CE, Menut KC, Pearlstein S, Liu C, Shen WT, Gosnell J, Sosa JA, Roman S, Duh QY, Suh I. Screening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea. Am J Med. 2022 Jan;135(1):60-66.
23. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004 Mar;89(3):1045-50.
24. Conn JW, Louis LH. Primary aldosteronism, a new clinical entity. Ann Intern Med. 1956;44:1–15. doi: 10.7326/0003-4819-44-1-1.
25. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–59. doi: 10.1016/S2213-8587(17)30367-4.
26. Nanba K, et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J Clin Endocrinol Metab. 2018;103:3869–3876. doi: 10.1210/jc.2018-01004.
27. Azizan EA, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45:1055–1060. doi: 10.1038/ng.2716.
28. Ross GP, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300. doi: 10.1016/j.jacc.2006.07.059.
29. Merrell RC. Aldosterone-producing tumors (Conn's syndrome) Semin Surg Oncol. 1990;6:66–70. doi: 10.1002/ssu.2980060203.
30. Choi M, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–772. doi: 10.1126/science.1198785.
31. Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med. 1967;66:1079–1090. doi: 10.7326/0003-4819-66-6-1079.
32. Monticone S, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–1820. doi: 10.1016/j.jacc.2017.01.052.
33. Azizan EA, et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa-and zona fasciculata-like tumors. J Clin Endocrinol Metab. 2012;97:E819–E829. doi: 10.1210/jc.2011-2965.
34. Grell GA, Hanchard B, Fletcher PR, Clarke WF, Williams W. Conn's syndrome. Case report and a review of the syndrome of primary aldosteronism (SOPA) West Indian Med J. 1984;33:48–54.
35. Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Somatic and inherited mutations in primary aldosteronism. J Mol Endocrinol. 2017;59:R47–R63. doi: 10.1530/JME-17-0035.
36. Monticone S, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41–50. doi: 10.1016/S2213-8587(17)30319-4.
37. Simpson F, Barnett A. Primary aldosteronism (Conn's syndrome): report of a case, and an analysis of published cases. Med J Aust. 1961;1:729–735.
38. Simpson SA, et al. Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism. Experientia. 1953;9:333–335.
39. Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Hum Hypertens. 1988;2:187–189.
40. Conn JW, Rovner DR, Cohen EL, Nesbit RM. Normokalemic primary aldosteronism: its masquerade as essential

hypertension. JAMA. 1966;195:21–26. doi: 10.1001/jama.1965.03090030022005.
41. De Sousa K, et al. Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension. 2020;75:1034–1044. doi: 10.1161/HYPERTENSIONAHA.119.14177.
42. Williams B, Brown MJ. Investigation of primary aldosteronism in patients with resistant hypertension — Authors' reply. Lancet Diabetes Endocrinol. 2018;6:600–601. doi: 10.1016/S2213-8587(18)30174-8.
43. Wang T, et al. Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands. Eur J Endocrinol. 2011;164:613–619. doi: 10.1530/EJE-10-1085.
44. Mulatero P, et al. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens. 2016;34:2253–2257. doi: 10.1097/HJH.0000000000001088.
45. Gomez-Sanchez CE, Oki K. Minireview: potassium channels and aldosterone dysregulation: is primary aldosteronism a potassium channelopathy? Endocrinology. 2014;155:47–55. doi: 10.1210/en.2013-1733.
46. Omata K, et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension. 2018;72:874–880. doi: 10.1161/HYPERTENSIONAHA.118.11086.
47. Yamada M, et al. KCNJ5 mutations in aldosterone-and cortisol-co-secreting adrenal adenomas. Endocr J. 2012;59:735–741. doi: 10.1507/endocrj.ej12-0247.
48. Funder JW. Primary aldosteronism and salt. Pflugers Arch. 2015;467:587–594. doi: 10.1007/s00424-014-1658-0.
49. Burton TJ, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2012;97:100–109. doi: 10.1210/jc.2011-1537.
50. Geller DS, et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117–3123. doi: 10.1210/jc.2008-0594.
51. Hiramatsu K, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients Arch Intern Med. 1981;141:1589–1593.
52. Nishimoto K, et al. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab. 2010;95:2296–2305. doi: 10.1210/jc.2009-2010.
53. Charmandari E, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97:E1532–E1539. doi: 10.1210/jc.2012-1334.
54. Lifton RP, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–265. doi: 10.1038/355262a0.
55. Cheng CJ, et al. Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance. J Clin Endocrinol Metab. 2015;100:E155–E163. doi: 10.1210/jc.2014-3009.
56. Maria AG, et al. Mosaicism for KCNJ5 causing early-onset primary aldosteronism due to bilateral adrenocortical hyperplasia. Am J Hypertens. 2020;33:124–130. doi: 10.1093/ajh/hpz172.
57. Drake WM, Brown MJ. In: Oxford Textbook of Endocrinology and Diabetes. 3rd. Wass JAH, et al., editors. Oxford University Press; 2022.
58. Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am J Physiol Cell Physiol. 2013;304:C532–C540. doi: 10.1152/ajpcell.00203.2012.